Fresenius Kabi raises 2012 outlook again

Fresenius Kabi has raised its business outlook for 2012 for the second time this year, thanks to the better-than-expected performance it has achieved thus far.

Its organic sales growth outlook for the 12-month period has been increased to approximately nine percent, while its margin for earnings before interest and taxes is now expected to come to around 20.5 percent.

This nine percent growth forecast is up from the previous prediction – made in June 2012 – of a range of seven to nine percent, and much higher than the company's original six to eight percent target.

The company posted substantial organic growth across all regions and product categories in the first half of 2012 and is well on track to achieve similarly strong results during the final six months.

Demand in the US is particularly high at present due to ongoing shortages of intravenous drugs, which are impacting Fresenius Kabi's competitors more seriously.

A company statement said: "Fresenius plans to invest the additional earnings contribution to reduce future interest expenses and optimise the maturity profile of the group's financial liabilities."